Pharmacokinetics and Safety of Ginsenoside Rd Following a Single or Multiple Intravenous Dose in Healthy Chinese Volunteers.

Xing Zeng,Yuanhui Deng,Yi Feng,Yiming Liu,Liu Yang,Yu Huang,Jing Sun,Weixiong Liang,Yongyuan Guan

DOI: https://doi.org/10.1177/0091270009344334

2010-01-01

Abstract:The pharmacokinetics and safety of ginsenoside Rd (Rd) were assessed in healthy Chinese volunteers. In the single‐dose study, a randomized, open‐label, 3‐way crossover design was used. Participants were assigned to receive 10, 45, or 75 mg Rd by intravenous infusion, with a 2‐week washout period between dosing periods. Plasma levels of Rd were found to be proportional to dose, with the mean Cmaxand AUC0‐∞ranging from 2.8 to 19.3 mg/L and 27.9 to 212.5 mg·h/L over the dose range studied. Ginsenoside Rd was slowly cleared from plasma (t1/2Z= 17.7–19.3 hours). In the multiple‐dose study, 10 mg Rd was administered once daily for 6 days. Slight drug accumulation was noted. The mean steady‐state Cmax, AUC0‐∞, and AUCsswere 4.0 mg/L, 51.7 mg·h/L, and 26.4 mg·h/L, respectively. The t1/2Zwas 20.5 hours, which was similar to the single‐dose value. Ginsenoside Rd was well tolerated with no pattern of dose‐related adverse events. It had a favorable pharmacokinetic and safety profile that enables the drug to be explored in future clinical studies that target patients with acute ischemic stroke.